GSK plc Investor Science Event Transcript
Welcome to the GSK event. I will hand you over to Jeff McLaughlin to introduce today's call. Jeff, please go ahead.
Good afternoon, and good morning. Welcome to GSK's Investor Science Event: Getting ahead of RSV disease in older adults. I'm Jeff McLaughlin from the GSK IR team and your moderator for today's call. We are here today for an update from the IDWeek 2022 Conference on GSK's vaccines portfolio, of which the highlight is the pivotal Phase III data on our vaccine candidate for the prevention of RSV in older adults.
As usual, the presentation materials are available on gsk.com and were sent to our distribution list earlier today. Please also note that the data presented on today's call are available on the IDWeek website and have been submitted for publication in a peer-reviewed scientific journal.
Moving to Slide 2. I want to remind you all of the usual cautionary statements regarding forward-looking statements. On Slide 3,we are joined today by Dr. Tony Wood, Chief Scientific Officer; Dr. Phil Dormitzer, Global Head of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |